Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1–S-Checkpoint-Compromised Cancers
Open Access
- 21 February 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5441-5460
Abstract
Cyclins A and B bind and activate their cognate cyclin-dependent kinase (CDK) to regulate progression through the S and G2/M phases of the cell cycle, respectively. Cyclins recruit substrates and regulators through the binding of an RxL motif with a Hydrophobic Patch (HP) on the cyclin surface. We recently disclosed the first class of passively permeable macrocyclic peptides that bind to the HP of both Cyclin A and Cyclin B and selectively kill cancer cells with high E2F activity. We used a lead example to demonstrate in vivo tumor regression in cell-line-derived xenograft models of small-cell lung cancer (SCLC) via intraperitoneal dosing. Here we describe the optimization of this series for drug-like properties and oral bioavailability, resulting in the discovery of a lead compound, which demonstrates tumor regression in CDX models of SCLC via oral dosing. We are currently evaluating Cyclin A/B inhibition in a Phase 1 clinical trial.Keywords
This publication has 39 references indexed in Scilit:
- Differences in Binding Affinity Among Cell-cycle CDK and Cyclin PairsJournal of Molecular Biology, 2025
- Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatmentPharmacological Research, 2024
- Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directionsCritical Reviews in Oncology/Hematology, 2024
- Mechanisms of Sensitivity and Resistance to CDK4/6 InhibitionCancer Cell, 2020
- Designing Orally Bioavailable Peptide and Peptoid Macrocycles2017
- Cell permeability beyond the rule of 5Advanced Drug Delivery Reviews, 2016
- Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical CandidatesChemistry & Biology, 2014
- CDK2/cyclinA inhibitors: Targeting the cyclinA recruitment site with small molecules derived from peptide leadsBioorganic & Medicinal Chemistry Letters, 2006
- Targeting protein–protein interactions for cancer therapyJournal of Molecular Medicine, 2005
- Cyclin-Dependent Kinase Inhibitors and Human Cancer1998